BMS Clinic · Medical Weight Management
Wegovy®
Personalized Medical
Weight Management Program
Starting with a medical assessment to understand the role of GLP-1 medications in weight management.
Combining dietary and lifestyle adjustments with ongoing follow-up to develop a health management plan tailored to individual needs.
Understanding Wegovy
What Is Wegovy®?
Wegovy® is a prescription medication containing semaglutide, a GLP-1 receptor agonist approved by Hong Kong’s drug regulatory authority for relevant indications.
- It mimics some of the physiological actions of the body’s natural GLP-1 hormone, helping influence appetite and feelings of fullness.
- It may help reduce energy intake and support weight management when combined with dietary and physical activity adjustments.
- Wegovy® is intended to form part of a long-term weight management approach and is not a substitute for a healthy lifestyle.
Once Weekly · Doctor-Supervised
Whether Wegovy® is suitable, as well as the appropriate dosage and any dose adjustments, should be determined with consideration of individual medical history, current medications, and tolerability.
- Active ingredient: Semaglutide
- Drug class: GLP-1 receptor agonist
- Legal classification: Prescription medicine in Hong Kong
How It Works
From Appetite Regulation to Long-Term Weight Management
Wegovy® does not directly “burn fat.” Its effects are related to appetite signaling and the regulation of gastric emptying. When combined with ongoing lifestyle management, it may help suitable individuals manage their weight.
Appetite Regulation
Acts on physiological pathways involved in appetite control, helping to reduce hunger and food intake.
01 / APPETITE
Satiety
May increase feelings of fullness after meals and may delay gastric emptying. Individual responses can vary.
02 / SATIETY
Ongoing Management
Emphasizes nutrition, physical activity, and regular medical follow-up rather than focusing only on short-term changes in body weight.
03 / LONG-TERM
Clinical Evidence
Weight Changes in Clinical Research
The STEP 1 randomized clinical trial included 1,961 adults with overweight or obesity who did not have diabetes and met the study eligibility criteria. Both groups received lifestyle intervention and were followed for 68 weeks.
Source: Wilding et al., NEJM 2021, STEP 1. The chart uses 20% as a common display scale and is not intended to predict individual outcomes.
Average Weight Reduction Observed in the Study
This figure applies only to the conditions and analysis described in the study. Actual outcomes may be influenced by diet, physical activity, treatment adherence, health status, and other factors. Individual results may vary.
Eligibility
Who May Consider a Medical Assessment?
Wegovy® does not directly “burn fat.” Its effects are related to appetite signaling and the regulation of gastric emptying. When combined with ongoing lifestyle management, it may help suitable individuals manage their weight.
Adults with Obesity
Adults with an initial BMI of 30 kg/m² or above may be assessed by a doctor to determine whether they meet the relevant indication and individual health needs.
With Weight-Related Health Conditions
Adults with an initial BMI of 27 kg/m² or above and at least one weight-related comorbidity, such as hypertension or dyslipidaemia.
Personalized Safety Assessment
A doctor will consider medical and medication history, risk factors, and weight management goals when assessing suitability; BMI is not the only determining factor.
Safety First
Side Effects, Precautions & Medical Assessment
Prescription weight management medications are not suitable for everyone. Before assessment, patients should provide their doctor with complete information about existing medical conditions, pregnancy plans, previous allergies, and current medications.
More Common Side Effects
Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, constipation, and abdominal pain may occur, with individual responses varying according to tolerability.
Conditions Requiring Careful Assessment
Patients with a history of pancreatitis or gallbladder disease, kidney problems, diabetes-related eye conditions, pregnancy, or plans to become pregnant should inform their doctor in advance.
Be Alert to Serious Symptoms
Seek medical attention promptly if persistent severe abdominal pain, a serious allergic reaction, or prolonged vomiting leading to dehydration occurs.
Personalised Care
BMS Clinic’s Approach to Weight Management
We approach weight management from a whole-health perspective, with a focus on individual needs, risk identification, and ongoing assessment.
01
Initial Medical Assessment
Review of weight and health history, existing medical conditions, current medications, diet, and lifestyle habits.
02
Personalized Management Approach
A doctor will assess whether prescription medication should be considered, together with the individual’s dietary, physical activity, and overall health management needs.
03
Ongoing Follow-Up
Weight changes, tolerability, lifestyle factors, and other relevant health indicators are reviewed according to the doctor’s recommendations.
Are Wegovy® and Ozempic® the same medication?
Both contain Semaglutide, but they are different brands and products. Their approved indications, available strengths, and prescribing considerations are not exactly the same and they should not be interchanged without medical advice.
Is Wegovy® used once a week?
Official Hong Kong information indicates that Wegovy® is a once-weekly injectable medication. Whether it should be used, adjusted, or temporarily stopped should be determined by a doctor according to the individual’s circumstances.
Can everyone lose around 15% of their body weight?
No. The 14.9% figure represents the average result observed over 68 weeks in a specific population in the STEP 1 study. It does not mean that every user will achieve the same outcome.
Does Wegovy® need to be combined with diet and exercise?
Yes. Wegovy® is used as part of a weight management approach that includes reduced calorie intake, increased physical activity, and ongoing medical follow-up. It does not replace a healthy lifestyle.
Can I purchase Wegovy®, stop using it, or increase the dose on my own?
This is not recommended. Wegovy® is a prescription medication in Hong Kong, and its suitability, safe use, and ongoing management should be assessed by a doctor.
FAQs
Frequently Asked Questions
This page is provided for health education, general medical information, and service introduction purposes only. It does not replace diagnosis, prescription, personalised weight management assessment, or medical advice from a Hong Kong-registered doctor or other qualified healthcare professional.
Wegovy® (semaglutide) is a prescription medication belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class. Whether it is appropriate for an individual should be assessed based on body mass index (BMI), weight-related health conditions, medical history, current medications, and relevant risk factors. The clinical study data presented on this page reflect average outcomes in specific study populations and do not represent or guarantee equivalent weight changes for every individual.
Wegovy® may cause gastrointestinal symptoms and other adverse reactions and is subject to specific contraindications, warnings, and prescribing precautions. Actual prescribing decisions, dose adjustments, administration frequency, and ongoing monitoring should follow the latest applicable Hong Kong-registered product information and a doctor's individual assessment. Do not purchase, use, adjust, or discontinue prescription medication without appropriate medical guidance. Seek prompt medical attention if severe or persistent adverse symptoms occur.
Learn More About Whether Wegovy® May Be Suitable for Your Weight Management Needs
Wegovy® is a prescription medication for weight management. Whether it is appropriate should be assessed based on BMI, weight-related health conditions, medical history, current medications, pregnancy plans, and individual tolerability. Prescribing, dose adjustments, and follow-up should be guided by a doctor and combined with dietary, physical activity, and ongoing lifestyle management rather than self-adjusting the dose, stopping treatment, or changing how the medication is used.
References
Medical References
- Novo Nordisk Hong Kong. Wegovy® Hong Kong Official Website .
- Drug Office, Department of Health, Hong Kong. Wegovy FlexTouch Hong Kong Registration Information (HK-67964) .
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002. doi:10.1056/NEJMoa2032183 .
- MIMS Hong Kong. Semaglutide — MIMS Hong Kong .
Medical information and approved indications may be updated. Before publication, the clinic doctor should verify the latest product information applicable in Hong Kong at that time.